HelpMeSee has partnered with new initiatives to address the global cataract blindness crisis, focusing on empowering women in ...

Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber ...

In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...

Cencora is acquiring Retina Consultants of America for $4.6 billion, with potential additional contingent consideration of ...

Vevye will be included in key formularies of major plan sponsors, covering over 25 million Medicare Part D beneficiaries ...

FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications for nAMD. The ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables ...

Pediatric cataract surgeries are more costly than adult procedures, with significant nonsurgical expenses like anesthesia and ...

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...